Significant advances are being made in screening and diagnosis which have the potential to radically reduce the costs, whilst improving the accessibility and reach of programmes.
In combination with advancements in medical products (3D Breast Ultrasound, Digital Tomosynthesis), AI for computer-aided diagnosis and broader adoption of digital patient & citizen engagement - screening services, patient experience and cost per QALY could be positively impacted in coming years.
Hitachi Ltd. said it is developing a simple urine test to screen for cancers of the breast and colon after trials with small numbers of patients helped it identify those suffering from the disease. Researchers will next conduct tests on a group of 200 breast cancer patients and 200 healthy people to help create a simple method to detect the disease and plans to apply for a patent, Sakairi said. In Japan, cancer causes economic losses including reduced working hours and medical expenses of approximately 10 trillion yen ($94 billion) a year, Hitachi said in a statement Tuesday. “We’re giving priority to breast cancer,” said Sakairi. “It affects a lot of women and unlike prostate cancer it starts at an early age.”